Authors' response to comments regarding risperidone versus olanzapine Markov model.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D006801:Humans; D008390:Markov Chains; D000077152:Olanzapine; D010349:Patient Compliance; D011618:Psychotic Disorders / Q000188:drug therapy*; D012107:Research Design; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine